Evidence map›Paper›PMID 34136407›Full record

ArticleFrontiers in oncology2021

The Prognosis and Oncological Predictor of Urachal Carcinoma of the Bladder: A Large Scale Multicenter Cohort Study Analyzed 203 Patients With Long Term Follow-Up.

Young Dong Yu, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Urachal Carcinomas: A Comprehensive Systematic Review and Meta-analysis.International braz j urol : official journal of the Brazilian Society of Urology
    Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 2 countries.

Young Dong YuDepartment of Urology, College of Medicine, CHA University, Bundang CHA Hospital, Seongnam, South Korea.
Young Hwii KoDepartment of Urology, Yeungnam University Hospital, Daegu, South Korea.
Jong Wook KimDepartment of Urology, Korea University College of Medicine, Seoul, South Korea.
Seung Il JungDepartment of Urology, Chonnam National University Medical School, Gwangju, South Korea.
Seok Ho KangDepartment of Urology, Korea University School of Medicine, Seoul, South Korea.
Jinsung ParkDepartment of Urology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, South Korea.
Ho Kyung SeoDepartment of Urology, Center for Urologic Cancer Hospital, Goyang, South Korea.
Hyung Joon KimDepartment of Urology, Myunggok Medical Research Institute, Konyang University College of Medicine, Daejeon, South Korea.
Byong Chang JeongDepartment of Urology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Tae-Hwan KimDepartment of Urology, Kyungpook National University College of Medicine, Daegu, South Korea.
Se Young ChoiDepartment of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, South Korea.
Jong Kil NamDepartment of Urology, Pusan National University Yangsan Hospital, Pusan, South Korea.
Ja Yoon KuDepartment of Urology, Pusan National University Hospital, Busan, South Korea.
Kwan Joong JooDepartment of Urology, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, South Korea.
Won Sik JangDepartment of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Young Eun YoonDepartment of Urology, Hanyang University Hospital, Seoul, South Korea.
Seok Joong YunDepartment of Urology, College of Medicine, Chungbuk National University, Chungbuk National University Hospital, Cheongju, South Korea.
Sung-Hoo HongDepartment of Urology, Seoul St Mary's Hospital, Seoul, South Korea.
Jong Jin OhDepartment of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.
Korea University · KRSungkyunkwan University · KRCHA University Bundang Medical Center · KRChonnam National University Hospital · KRChung-Ang University Hospital · KRChungbuk National University Hospital · KREulji University · KRHanyang University Seoul Hospital · KRKonyang University · KRKyungpook National University · KRNational Cancer Center · USPusan National University Hospital · KRPusan National University Yangsan Hospital · KRSeoul National University Bundang Hospital · KRSeverance Hospital · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRYeungnam University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study evaluated the prognosis and survival predictors for bladder urachal carcinoma (UC), based on large scale multicenter cohort with long term follow-up database.

methodsA total 203 patients with bladder UC treated at 19 hospitals were enrolled. Clinical parameters on carcinoma presentation, diagnosis, and therapeutic methods were reviewed for the primary cancer and for all subsequent recurrences. The stage of UC was stratified by Mayo and Sheldon pathological staging system. Oncological outcomes and the possible clinicopathological parameters associated with survival outcomes were investigated.

resultsThe mean age of the patients was 54.2 years. Among the total of 203 patients, stages I, II, III, and IV (Mayo stage) were 48 (23.8%), 108 (53.5%), 23 (11.4%), and 23 (11.4%), respectively. Gross hematuria and bladder irritation symptoms were the two most common initial symptoms. The mean follow-up period was 65 months, and 5-year overall survival rates (OS), cancer-specific survival rates (CSS), and recurrence-free survival rates (RFS) were 88.3, 83.1, and 63.9%, respectively. For the patients with Mayo stage ≥III, OS, CSS, and RFS were significantly decreased to 38.0, 35.2, and 28.4%, respectively. The higher pathological stage (Mayo stage ≥III, Sheldon stage ≥IIIc), positive surgical margin (PSM), and positive lymphovascular invasion (PLM) were independent predictors of shorter OS, CSS, and RFS.

conclusionThe pathological stage, PSM, and PLM were significantly associated with the survival of UC patients, emphasizing an importance of the complete surgical resection of tumor lesion.

Indexed as

bladderlymphovascular invasionsurgical marginsurvival rateurachal carcinoma

Identifiers

PMID34136407
PMCPMC8202399
OpenAlexW3168429052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.